All In Biotech

Drug Trial Radar · NCT07827027

Evaluation of the Bioequivalence of RAY1225 Injection in Healthy Participants

Evaluation of the Bioequivalence of RAY1225 Injection in Healthy Participants in a Single-center, Randomized, Open-label, Parallel Study

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

68

Planned (sponsor's estimate)

Start

Sep 21, 2026

Primary completion

Nov 5, 2026

Study completion Dec 2, 2026

Sponsor

Sponsor type
Industry
First posted
Sep 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-center, randomized, open, parallel-designed bioequivalence study aimed at evaluating the pharmacokinetic differences of RAY1225 injection after site and batch changes compared to before the changes.

Conditions

  • Basic Science

Interventions

  • RAY1225Drug

    Single subcutaneous injection of RAY1225 3mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of RAY1225 From Time Zero to T (AUC[0-t])Time frame: Baseline through Day 43
  2. PK: Maximum Concentration of RAY1225Time frame: Baseline through Day 43

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.